This article is more than 5 years old. Information may no longer be current.

LASEK with MMC prevents haze in patients unsuitable for LASIK

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LONDON — Mitomycin-C can allow surgeons to perform LASEK in patients who are unsuitable for LASIK, according to a surgeon speaking here.

Iwona Liberek, MD, of the Medical University of Warsaw, Poland, reviewed her 2-year results of 968 patients treated with LASEK and with 0.02% mitomycin-C (MMC) for medium to high refractive errors. She presented her findings at the European Society of Cataract and Refractive Surgeons annual meeting.

Patients had been selected for LASEK because of insufficient corneal thicknesses for LASIK, Dr. Liberek said. MMC was applied with a Spongostan film for 0.5 to 1 minute after ablation.

At 28 months' follow-up, late haze had appeared in just 61 patients, she said, noting no patients required re-operation.

"For the LASEK procedure, the use of mitomycin-C allows for qualifying patients with large errors for whom it would be dangerous to undergo the LASIK procedure," Dr. Liberek said.

"Based on 2 years of observation, the use of mitomycin-C seems to be a safe method to prevent such complications as haze, which is confirmed by confocal microscope examination," she said.